Table 2.
Demographic and Baseline Characteristics of Patients With MDD Treated With Desvenlafaxine (safety population)
| Relapse Prevention Studyb |
|||||
| Short-Term, All Studiesa |
Open-Label Phase, Desvenlafaxine, 200–400 mg | Double-Blind Phase |
|||
| Characteristic | Placebo | Desvenlafaxine, 50–400 mg | Placebo | Desvenlafaxine, 200–400 mg | |
| Safety population, n | 1,116 | 1,834 | 594 | 185 | 190 |
| ITT population, n | 1,108 | 1,805 | 575 | 185 | 189 |
| Age, mean (SD), y | 42.4 (12.7) | 42.5 (12.6) | 41.9 (12.6) | 42.8 (11.8) | 42.7 (12.3) |
| Weight, mean (SD), kg | 79.0 (19.7)c | 79.9 (20.0) | 77.5 (19.3) | 76.8 (18.7) | 78.7 (19.6) |
| Ethnicity, n (%)d | |||||
| Asian | 10 (1) | 20 (1) | 12 (2) | 4 (2) | 1 (1) |
| Black | 105 (9) | 156 (9) | 36 (6) | 8 (4) | 11 (6) |
| Hispanic | 66 (6) | 121 (7) | 33 (6) | 7 (4) | 7 (4) |
| Other | 21 (2) | 25 (1) | 5 (1) | 2 (1) | 2 (1) |
| White | 909 (81) | 1,504 (82) | 503 (85) | 161 (87) | 169 (89) |
| Sex, n (%) | |||||
| Female | 713 (64) | 1,111 (61) | 404 (68) | 126 (68) | 127 (67) |
| Male | 403 (36) | 723 (39) | 190 (32) | 59 (32) | 63 (33) |
a
DeMartinis et al,13 Septien-Velez et al,14 Liebowitz et al,16 Liebowitz et al,17 Lieberman et al,18 Feiger et al,20 Boyer et al,21 and Wyeth Pharmaceuticals.22
b
Rickels et al.19
c
n = 1,115.
d
Percent totals may not equal 100 due to rounding.
Abbreviations: ITT = intent-to-treat; SD = standard deviation.